Comparative Pharmacology
Head-to-head clinical analysis: SOLOSEC versus TINIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOLOSEC versus TINIDAZOLE.
SOLOSEC vs TINIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Secnidazole is a nitroimidazole antibiotic that exerts its bactericidal activity by entering the bacterial cell and inhibiting DNA synthesis. The nitro group of secnidazole is reduced intracellularly to form free radicals and other reactive intermediates that damage bacterial DNA.
Tinidazole is a nitroimidazole antibiotic that diffuses into microorganisms where it is reduced by bacterial nitroreductases to form reactive cytotoxic intermediates that damage DNA and inhibit protein synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
2 g orally as a single dose for trichomoniasis.
2 g orally once daily for 2 days; alternatively, 1 g orally once daily for 5 days for trichomoniasis. For bacterial vaginosis: 2 g orally once daily for 2 days. For giardiasis: 2 g orally as a single dose. For amebiasis: 2 g orally once daily for 3 days for intestinal amebiasis; 2 g orally once daily for 5 days for hepatic amebiasis.
None Documented
None Documented
Clinical Note
moderateTinidazole + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tinidazole."
Clinical Note
moderateTinidazole + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Tinidazole."
Clinical Note
moderateTinidazole + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Tinidazole."
Clinical Note
moderateTinidazole + Fluconazole
Terminal elimination half-life approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment
The terminal elimination half-life is approximately 12-14 hours in healthy adults, which supports once-daily dosing. In hepatic impairment, half-life may be prolonged.
Renal: approximately 75% as unchanged drug; fecal/biliary: minor (estimated <10%)
Following oral administration, approximately 20-25% of the dose is excreted unchanged in urine, with an additional 10-15% as metabolites. Fecal excretion accounts for about 50% of the dose, primarily as metabolites. Biliary excretion is a minor route.
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic
"The metabolism of Fluconazole can be decreased when combined with Tinidazole."